Pfizer in talks over full license for COVID-19 vaccine in Singapore

Pfizer-BioNTech's COVID-19 vaccine has interim authorisation under the pandemic special access route in Singapore

  
Vials with Pfizer-BioNTech and AstraZeneca coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. Image used for illustrative purpose

Vials with Pfizer-BioNTech and AstraZeneca coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. Image used for illustrative purpose

REUTERS/Dado Ruvic/Illustration

SINGAPORE- Pfizer Inc is in discussions with Singapore's Health Sciences Authority regarding obtaining a full license application for its COVID-19 vaccine, the company said in response to a query from Reuters.

Pfizer-BioNTech's COVID-19 vaccine has interim authorisation under the pandemic special access route in Singapore. The U.S. Food and Drug Administration granted full approval to the vaccine last month. 

(Reporting by Aradhana Aravindan in Singapore Editing by Ed Davies) ((aradhana.aravindan@thomsonreuters.com;))


More From Global